Jump to content

Pipofezine

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Vanished user 0x8cSXE0x6 (talk | contribs) at 10:40, 27 September 2017. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Pipofezine
Clinical data
Trade namesAzafen, Azaphen
Routes of
administration		Oral
ATC code
  • none
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • 5-methyl-3-(4-methylpiperazin-1-yl)pyridazino[3,4-b][1,4]benzoxazine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC16H19N5O
Molar mass297.36 g/mol g·mol−1

Pipofezine, sold under the brand name Azafen or Azaphen, is a tricyclic antidepressant (TCA) approved in Russia for the treatment of depression.[1][2][3][4] It was introduced in the late 1960s and is still used today.[5][6]

Pipofezine has been shown to act as a potent inhibitor of the reuptake of serotonin.[7][8] In addition to its antidepressant action, pipofezine has sedative effects as well, suggesting antihistamine activity.[4] Other properties such as anticholinergic or antiadrenergic actions are less clear but are likely.[citation needed]

See also

References

  1. ^ Aleeva GN, Molodavkin GM, Voronina TA (July 2009). "Comparison of antidepressant effects of azafan, tianeptine, and paroxetine". Bulletin of Experimental Biology and Medicine. 148 (1): 54–6. doi:10.1007/s10517-009-0638-4. PMID 19902096.
  2. ^ Swiss Pharmaceutical Society (2000). Index Nominum 2000: International Drug Directory (Book with CD-ROM). Boca Raton: Medpharm Scientific Publishers. ISBN 3-88763-075-0.
  3. ^ European Drug Index, 4th Edition. Boca Raton: CRC Press. 1998. ISBN 3-7692-2114-1.
  4. ^ a b John E. Macor (2009). Annual Reports in Medicinal Chemistry, Volume V44. Boston: Academic Press. ISBN 0-12-374766-X.
  5. ^ Mashkovskii MD; Polezhaeva AI; Avrutskii GIa; Vertozgadova OP; Smulevich AB (1969). "[The pharmacologic properties and therapeutic effectiveness of the new antidepressant preparation Azaphen]". Zhurnal Nevropatologii I Psikhiatrii Imeni S.S. Korsakova (Moscow, Russia : 1952) (in Russian). 69 (8): 1234–8. PMID 5392529.
  6. ^ Shinaev NN, Akzhigitov RG (2005). "[Azaphen: a return to clinical practice]". Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova / Ministerstvo Zdravookhraneniia I Meditsinskoĭ Promyshlennosti Rossiĭskoĭ Federatsii, Vserossiĭskoe Obshchestvo Nevrologov [I] Vserossiĭskoe Obshchestvo Psikhiatrov (in Russian). 105 (10): 55–6. PMID 16281382.
  7. ^ Avdulov NA, Maĭsov NI (November 1981). "[Atypical antidepressants: effect on synaptosomal uptake of serotonin and GABA]". Biulleten' Eksperimental'noĭ Biologii I Meditsiny (in Russian). 92 (11): 564–6. PMID 7198493.
  8. ^ Valdman AV, Avdulov NA, Rozganets VV, Rusacov DY (1983). "Behavioural and neurochemical studies of the action of atypical antidepressants". Acta Physiologica et Pharmacologica Bulgarica. 9 (3): 3–10. PMID 6142583.


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Pipofezine&oldid=802620679"